Intervention not reported
Quality of life · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT
The intervention showed no clear difference in progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer ‐ extended RAS MT
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer ‐ extended RAS MT
The intervention showed no clear difference in tumour response rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review